Cargando…

24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease

Levodopa-carbidopa intestinal gel (LCIG) is effective for the control of motor fluctuations in Parkinson’s disease (PD). The objective of this study is to report the reduction of dyskinesias after transitioning from 16 to 24-h/day LCIG infusion. From a cohort of 74 PD patients treated with LCIG for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruse, Belinda, Morales-Briceño, Hugo, Chang, Florence C F, Mahant, Neil, Ha, Ainhi D, Kim, Samuel D, Wolfe, Nigel, Kwan, Vu, Tsui, David S, Griffith, Jane M, Galea, Donna, Fung, Victor S C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243994/ https://www.ncbi.nlm.nih.gov/pubmed/30480087 http://dx.doi.org/10.1038/s41531-018-0070-4

Ejemplares similares

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations
por: Thakkar, Sandeep, et al.
Publicado: (2021)

Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
por: Freire‐Alvarez, Eric, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

A single centre prospective study of three device-assisted therapies for Parkinson’s disease
por: Morales-Briceño, Hugo, et al.
Publicado: (2023)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
por: Oshiro, Saki, et al.
Publicado: (2021)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Proposition of zinc supplementation during levodopa–carbidopa intestinal gel treatment
por: Matsuyama, Hirofumi, et al.
Publicado: (2018)

Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
por: Bautista, Juan Miguel Pilar, et al.
Publicado: (2020)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
por: GÜLTEKİN, Murat, et al.
Publicado: (2020)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
por: Pauls, K. Amande M., et al.
Publicado: (2021)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
por: Szász, József Attila, et al.
Publicado: (2021)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa‐carbidopa Intestinal Gel
por: Fernandez, Hubert H., et al.
Publicado: (2015)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016)

Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
por: Rosebraugh, Matthew, et al.
Publicado: (2019)

Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
por: SÜCÜLLÜ KARADAĞ, Yeşim, et al.
Publicado: (2021)

Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study
por: Fasano, Alfonso, et al.
Publicado: (2021)

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014)

Xanthonychia Due to Staining From Carbidopa-Levodopa
por: Hwang, Jonathan Kyle, et al.
Publicado: (2023)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f675qi4o434ccu10bvnm8eb7nh